Results announcement for the first quarter 2012
- Sales growth of +2% CER - Further R&D delivery, operational leverage and continued returns to shareholders - Core EPS 27.3p (+7%), dividend up 6% to 17p
Issued: London UK
- Sales growth of +2% CER
- Further R&D delivery, operational leverage and continued returns to shareholders
- Core EPS 27.3p (+7%), dividend up 6% to 17p
Full announcement and CFO video available in the Investors section of this website.
|
GlaxoSmithKline Enquiries: |
|||||
|
UK Media enquiries: |
David Mawdsley |
+44 (0) 20 8047 5502 |
(London) |
||
|
|
Stephen Rea |
+44 (0) 20 8047 5502 |
(London) |
||
|
|
Sarah Spencer |
+44 (0) 20 8047 5502 |
(London) |
||
|
|
David Daley |
+44 (0) 20 8047 5502 |
(London) |
||
|
|
|
|
|
||
|
US Media enquiries: |
Kevin Colgan |
+1 919 483 2839 |
(North Carolina) |
||
|
|
Melinda Stubbee |
+1 919 483 2839 |
(North Carolina) |
||
|
|
Sarah Alspach |
+1 919 483 2839 |
(Washington, DC) |
||
|
|
Jennifer Armstrong |
+1 919 483 2839 |
(Philadelphia) |
||
|
|
|||||
|
Analyst/Investor enquiries: |
Sally Ferguson |
+44 (0) 20 8047 5543 |
(London) |
||
|
Tom Curry |
+ 1 215 751 5419 |
(Philadelphia) |
|||
|
Gary Davies |
+ 44 (0) 20 8047 5503 |
(London) |
|||
|
Jeff McLaughlin |
+ 1 215 751 7002 |
(Philadelphia) |
|||
|
Ziba Shamsi |
+ 44 (0) 20 8047 3289 |
(London) |
|||
